61. Autoimmune hemolytic anemia Clinical trials / Disease details


Clinical trials : 137 Drugs : 127 - (DrugBank : 55) / Drug target genes : 26 - Drug target pathways : 153

  
13 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05057468
(ClinicalTrials.gov)
October 20, 202116/9/2021Second-line Treatment of Primary Autoimmune Hemolytic AnemiaCyclosporine as a Second-line Treatment of Primary Autoimmune Hemolytic AnemiaPrimary Autoimmune Hemolytic AnemiaDrug: Cyclosporine;Drug: RituximabAssiut UniversityNULLRecruiting18 YearsN/AAll30Phase 3Egypt
2NCT05057481
(ClinicalTrials.gov)
September 15, 202116/9/2021Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus ErythematosusReappraisal of Second-line Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus ErythematosusAutoimmune Hemolytic Anemia;Systemic Lupus ErythematosusDrug: Mycophenolate Mofetil 500mg;Drug: RituximabAssiut UniversityNULLActive, not recruiting18 YearsN/AAll30Phase 3Egypt
3EUCTR2016-002478-11-AT
(EUCTR)
19/07/201601/07/2016Very low doses of Rituximab for autoimmune diseases, for which rituximab is not approved for - a Pilot TrialVery low doses of Rituximab for off-label treatment – a Pilot Trial - Low_Rituximab Autoimmune-haemolytic AnemiaAntiphospholipid SyndromeImmune-mediated Thrombocytopenia
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000154058
MedDRA version: 20.0;Classification code 10023095;Term: ITP;System Organ Class: 100000157088
MedDRA version: 20.0;Level: PT;Classification code 10002817;Term: Antiphospholipid syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Mabthera or biosimilar Rituximab
Product Name: Rituximab
Product Code: Rituximab
INN or Proposed INN: RITUXIMAB
Other descriptive name: Rituximab
Medical University of Vienna, Department of Internal medicine INULLNot RecruitingFemale: yes
Male: yes
48Phase 2Austria
4EUCTR2011-004835-30-FI
(EUCTR)
10/07/201317/06/2013Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy.Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy. - CAD5 Primary chronic cold agglutinin disease requiringtreatment;Therapeutic area: Diseases [C] - Cancer [C04]Trade Name: Levact
INN or Proposed INN: BENDAMUSTINE HYDROCHLORIDE
Trade Name: MabThera
INN or Proposed INN: RITUXIMAB
Department of Medicine, Haugesund HospitalNULLNot RecruitingFemale: yes
Male: yes
50Phase 2Finland;Denmark;Norway
5EUCTR2011-004835-30-DK
(EUCTR)
17/01/201330/11/2012Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy.Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy. - CAD5 Primary chronic cold agglutinin disease requiringtreatment;Therapeutic area: Diseases [C] - Cancer [C04]Trade Name: Levact
INN or Proposed INN: BENDAMUSTINE HYDROCHLORIDE
Trade Name: MabThera
INN or Proposed INN: RITUXIMAB
Department of Medicine, Haugesund HospitalNULLNot RecruitingFemale: yes
Male: yes
50Phase 2Finland;Denmark;Norway
6NCT02689986
(ClinicalTrials.gov)
January 201316/2/2016Bendamustine and Rituximab Combination Therapy for Cold Agglutinin DiseaseThe CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination TherapyCold Agglutinin Disease;Autoimmune Hemolytic AnemiaDrug: Bendamustine, RituximabHelse FonnaNULLCompleted18 YearsN/AAll43Phase 2Denmark;Finland;Norway
7EUCTR2011-004835-30-NO
(EUCTR)
23/10/201229/08/2012Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy.Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter trial on the safetyand efficacy of bendamustine and rituximab combinationtherapy. - CAD5 Primary chronic cold agglutinin disease requiringtreatment;Therapeutic area: Diseases [C] - Cancer [C04]Trade Name: Levact
INN or Proposed INN: BENDAMUSTINE HYDROCHLORIDE
Trade Name: MabThera
INN or Proposed INN: RITUXIMAB
Department of Medicine, Haugesund HospitalNULLNot RecruitingFemale: yes
Male: yes
50Phase 2Finland;Denmark;Norway
8NCT01181154
(ClinicalTrials.gov)
March 3, 201112/8/2010Rituximab in Auto-Immune Hemolytic AnemiaRituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled TrialWarm Autoimmune Hemolytic AnemiaDrug: rituximab (Mabthera®);Drug: PlaceboAssistance Publique - Hôpitaux de ParisHoffmann-La RocheCompleted18 YearsN/AAll32Phase 3France
9NCT00960713
(ClinicalTrials.gov)
June 200916/7/2009The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune DisordersThe RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune DisordersPemphigus;Auto-immune Thrombocytopenic Purpura;Hemolytic Auto-immune Anaemia;Cold Agglutinin Disease;CryoglobulinemiaDrug: Rituximab (MABTHERA® or RITUXAN®).University Hospital, ToulouseNULLCompleted18 YearsN/ABoth35N/AFrance
10NCT01345708
(ClinicalTrials.gov)
January 200928/4/2011A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic AnemiaA Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Disease (Cold Type) (Warm Type)Drug: prednisone, low dose rituximabFondazione OspedaleUniversity Hospital, Udine, ItalyCompleted18 YearsN/ABoth23Phase 2Italy
11EUCTR2008-006713-25-IT
(EUCTR)
23/09/200816/01/2009A SINGLE-ARM PILOT STUDY WITH LOW-DOSE RITUXIMAB PLUS STANDARD ORAL PREDNISONE IN IDIOPATHIC AUTOIMMUNE HEMOLYTIC ANEMIA - NDA SINGLE-ARM PILOT STUDY WITH LOW-DOSE RITUXIMAB PLUS STANDARD ORAL PREDNISONE IN IDIOPATHIC AUTOIMMUNE HEMOLYTIC ANEMIA - ND ANEMIE EMOLITICHE AUTOIMMUNI IDIOPATICHEINN or Proposed INN: RituximabOSPEDALE MAGGIORE DI MILANO (IRCCS)NULLNot RecruitingFemale: yes
Male: yes
Italy
12NCT00373594
(ClinicalTrials.gov)
June 20057/9/2006Therapy for Chronic Cold Agglutinin DiseaseTherapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine.Cold Agglutinin DiseaseDrug: Rituximab;Drug: FludarabineUniversity of BergenNULLCompleted18 Years90 YearsBoth30Phase 2Norway;Russian Federation
13NCT01134432
(ClinicalTrials.gov)
March 200528/5/2010Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic AnemiaAnti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial.Anemia, Hemolytic, AutoimmuneDrug: prednisolone + mabthera;Drug: PrednisoloneCopenhagen University Hospital at HerlevNULLCompleted18 YearsN/ABoth65Phase 3Denmark